Phase 4 N=300 Clinical Study of Lipoic Acid on Ischemic Heart Failure
Ischemic Heart Failure
Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
Phase 3 N=121 Heart Rate Reduction in Heart Failure
Heart Failure
Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters
N/A N=19 High Intensity Interval Exercise in Diastolic Heart Failure
Diastolic Heart Failure
Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade
Phase 4 N=697 Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease
Ischemic Heart Disease
Primary: Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement — 140 participants
Phase 4 N=55 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Heart Failure, Diastolic · Diastolic Heart Failure · Hypertension
Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio
Phase 4 N=777 ISCHEMIA-Chronic Kidney Disease Trial
Cardiovascular Diseases · Coronary Artery Disease · Heart Diseases
Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants
Phase 3 N=40 Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Heart Disease, Ischemic · Atherosclerosis, Coronary
Primary: Magnetic Resonance Image Quality Rating — 3.57; 2.55 units on a likert scale — p=<0.001
N/A N=335 Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
Phase 4 N=28 Ranolazine in Ischemic Cardiomyopathy
Cardiomyopathy · Chest Pain · Dyspnea
Primary: Anginal Frequency — 86.67; 74.44 units on a scale — p=0.058
Phase 3 N=380 Metformin to Reduce Heart Failure After Myocardial Infarction
ST Elevation Myocardial Infarction (STEMI) · Coronary Artery Disease · Heart Failure
Primary: Improvement in Left Ventricular Ejection Fraction — 53.1; 54.8 % of LVEF
Early Phase 1 N=30 Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure
Heart Failure
Primary: Blood Flow — 300; 275 ml/min
Phase 2 N=130 Thiamine and Acute Decompensated Heart Failure: Pilot Study
Heart Failure · Diabetes
Primary: Effect of Thiamine Supplementation on Dyspnea — 34; 32 mm
Phase 1 N=48 The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy
Heart Failure · Cardiomyopathies
Primary: Change From Baseline in Markers of Cardiac Collagen Turnover (PINP) in Patients With Systolic Heart Failure and Compared With Healthy Controls. — 48.1; 48.1; 39 ng/ml…
Phase 2 N=30 Sodium Nitrite in Acute Myocardial Infarction
Acute Myocardial Infarction
Primary: Ischemia Area at Risk as Determined by Paired Single-photon Computed Tomography Studies With Technetium Tc99m Sestamibi.
Phase 3 N=133 PUFAs and Left Ventricular Function in Heart Failure
Dilated Cardiomyopathy · Heart Failure
Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…
N/A N=400 Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)
Heart Failure
Primary: Percent of Subjects With an Attempted Implant of the Chronicle ICD System Free From System-related Chronicle ICD Complications at 6-months Post-implant. — 90.5…
N/A N=100 Exercise Intolerance in Elderly Patients With Diastolic Heart Failure
Heart Failure, Diastolic · Obesity
Primary: Exercise Capacity — 15.5; 15.5; 14.1; 16.6 ml/kg/min — p=<0.001
N/A N=45 Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit
Heart Failure
Primary: Oxygen Uptake (VO2) Peak — 1778.1; 1228.2; 1393.7; 1763.6 ML/KG/Min
Phase 3 N=110 Myocardial Ischemia and Transfusion Pilot
Myocardial Infarction · Unstable Angina · Coronary Artery Disease
Primary: Hemoglobin Concentration — 10.30; 9.03; 10.78; 8.98 g/dL — p=<0.001
Phase 2 N=92 Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)
Chronic Ischemic Heart Disease · Left Ventricular Dysfunction · Angina
Primary: Change in Maximal Oxygen Consumption (VO2max) — -0.6; 0.4 mL/kg/min — p=0.169
Phase 2 N=23 A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
Non-Ischemic Heart Failure
Primary: Safety Will be Evaluated by Number of AE — 38; 35; 1; 1 number of events
Phase 2 N=23 Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
N/A N=19 Sex and Obesity: Effects on Heart Failure Study
Obesity · Heart Failure
Primary: Average Myocardial Blood Flow — 0.73; 0.97 mL/g/minute — p=<0.005
Phase 3 N=50 METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure (METIS Trial)
Heart Failure · Myocardial Ischemia
Primary: Change in Physical Capacity Measured Using the 6-minute Walk Test Distance — 24.5; 21.3 meters
N/A N=349 Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
Death · Congestive Heart Failure
Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…
Phase 4 N=127 Responses of Myocardial Ischemia to Escitalopram Treatment
Myocardial Ischemia
Primary: Percentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors — 34.2; 17.5 percentage of participants
Phase 3 N=3,506 Myocardial Ischemia and Transfusion
Myocardial Infarction · Anemia
Primary: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction — 255; 295 Participants
N/A N=319 Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization
Cardiovascular Diseases · Coronary Disease · Heart Failure
Primary: Survival Free of Cardiac Hospitalization